INOSINE: 22 Adverse Event Reports & Safety Profile
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
22
Total FAERS Reports
4 (18.2%)
Deaths Reported
5
Hospitalizations
22
As Primary/Secondary Suspect
First Report: 2007 · Latest Report: 20240713
What Are the Most Common INOSINE Side Effects?
#1 Most Reported
Drug hypersensitivity
8 reports (36.4%)
#2 Most Reported
Vomiting
7 reports (31.8%)
#3 Most Reported
Toxicity to various agents
7 reports (31.8%)
All INOSINE Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Drug hypersensitivity | 8 | 36.4% | 0 | 0 |
| Allergy to vaccine | 7 | 31.8% | 0 | 0 |
| Atrial flutter | 7 | 31.8% | 0 | 0 |
| Bronchitis chronic | 7 | 31.8% | 0 | 0 |
| Coronary artery occlusion | 7 | 31.8% | 0 | 0 |
| Diarrhoea | 7 | 31.8% | 0 | 0 |
| Diverticulum | 7 | 31.8% | 0 | 0 |
| Essential hypertension | 7 | 31.8% | 0 | 0 |
| Exposure to toxic agent | 7 | 31.8% | 0 | 0 |
| Gastrooesophageal reflux disease | 7 | 31.8% | 0 | 0 |
| Lung disorder | 7 | 31.8% | 0 | 0 |
| Mitral valve prolapse | 7 | 31.8% | 0 | 0 |
| Obstructive airways disorder | 7 | 31.8% | 0 | 0 |
| Palpitations | 7 | 31.8% | 0 | 0 |
| Pyrexia | 7 | 31.8% | 0 | 0 |
| Rash | 7 | 31.8% | 0 | 0 |
| Scoliosis | 7 | 31.8% | 0 | 0 |
| Throat tightness | 7 | 31.8% | 0 | 0 |
| Toxicity to various agents | 7 | 31.8% | 4 | 2 |
| Vomiting | 7 | 31.8% | 0 | 0 |
Who Reports INOSINE Side Effects? Age & Gender Data
Gender: 61.9% female, 38.1% male. Average age: 48.4 years. Most reports from: US. View detailed demographics →
Is INOSINE Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2007 | 5 | 0 | 0 |
| 2008 | 2 | 0 | 0 |
| 2021 | 4 | 4 | 0 |
| 2022 | 2 | 0 | 2 |
| 2024 | 1 | 0 | 0 |
What Is INOSINE Used For?
| Indication | Reports |
|---|---|
| Product used for unknown indication | 10 |
Official FDA Label for INOSINE
Official prescribing information from the FDA-approved drug label.